Lupin Launches Ajaduo M Forte, a Triple Fixed-Dose Combination of Empagliflozin, Linagliptin, and Metformin Extended Release (ER)
Global pharmaceutical company Lupin Limited has announced the launch
of Ajaduo M Forte, a novel triple
fixed-dose combination (FDC) therapy for the management of Type 2 Diabetes Mellitus (T2DM) in India.
Ajaduo M Forte combines three well-established
agents- Empagliflozin, Linagliptin, and
Metformin Extended Release (ER)- into a single daily tablet, simplifying
treatment regimens for patients struggling with diabetes and its associated
complications.
The product will be available in two
strengths:
- Ajaduo M Forte 25: Empagliflozin 25 mg +
Linagliptin 5 mg + Metformin ER 1000 mg at 21 Rs/ Tab - Ajaduo M Forte 10: Empagliflozin 10 mg +
Linagliptin 5 mg + Metformin ER 1000 mg at 19 Rs/Tab
Empagliflozin, an SGLT2 inhibitor, promotes urinary glucose excretion and offers
cardiovascular and renal benefits. Linagliptin,
a DPP-4 inhibitor, enhances incretin levels to improve insulin secretion and
reduce glucagon release. Metformin ER
improves insulin sensitivity and suppresses hepatic glucose production.
With its focused Fixed dose combinations,
Ajaduo M Forte specifically targets multiple pathophysiological defects
described in the Ominous Octet model,
addressing key contributors such as insulin resistance, beta-cell dysfunction,
and increased renal glucose reabsorption. It is the only USFDA-approved
fixed-dose triple combination of Empagliflozin, Linagliptin, and Metformin,
providing a comprehensive approach to glycemic control. The formulation aligns
with globally recognized guidelines, including those issued by the ADA/EASD and RSSDI, reinforcing its clinical relevance and utility in modern
diabetes management.
Commenting on the
launch, Mr Gagan Arora, Vice President Sales and Marketing, “Ajaduo M Forte reflects our commitment to
delivering innovative, patient-centric solutions. This triple combination
simplifies therapy while offering robust efficacy aligned with international
recommendations, enabling better long-term outcomes for diabetes patients in
India.”
With Empagliflozin going off-patent, Lupin has
strategically expanded its diabetes portfolio by launching Ajaduo, a fixed-dose
combination (FDC) of Empagliflozin and Linagliptin, available in Ajaduo 10/5
and Ajaduo 25/5. Additionally, the company has introduced Ajaduo M Forte, a
triple FDC of Empagliflozin, Linagliptin, and Metformin Extended Release,
available in Ajaduo M Forte 25 and Ajaduo M Forte 10.
You can
read about it at the link below: